M6P Therapeutics is developing the next-generation enzyme replacement and gene therapies for lysosomal storage disorders. We have discovered a novel method for significantly increasing mannose-6-phosphate phosphorylation of various lysosomal enzymes. This allows for markedly improved enzyme delivery to target tissues and promises improved clinical outcomes.
Location: United States, Missouri, Saint Louis
Employees: 11-50
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | 6 Dimensio... | 6dimension... |
Mentions in press and media 2
| Date | Title | Description |
| 01.07.2026 | Pompe Disease Therapy Nexviazyme Clears Infant Phase 3, FDA Filing Set | By John Bright Published: Jul 01 2026, 2:33 PM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 25.06.2021 | Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021 | NEWPORT BEACH, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Roth Capital Partners (“Roth”), www.roth.com, is set to virtually present the Roth Virtual Healthcare Private Company Forum on June 28th, 2021. This event will con... |